ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Free Cash Flow
    • Future ETFs
    • Global Diversification
    • Gold/Silver/Critical Minerals
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Megatrends
    • Modern Alpha
    • Multi-Asset
    • Night Effect
    • Portfolio Strategies
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • Company
    • About VettaFi
    • Get VettaFi’ed
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Disruptive Technology Channel
  2. These Segments May Power ARK Genomics ETF
Disruptive Technology Channel
Share

These Segments May Power ARK Genomics ETF

Tom LydonFeb 24, 2023
2023-02-24

Genomics is one of the epicenters of healthcare innovation and that will remain true for years to come. For investors looking to tap into that theme, it pays to examine some of the catalysts that will facilitate long-term upside for genomics equities.

Fortunately, that endeavor doesn’t require a lot of legwork because exchange traded funds such as the ARK Genomic Revolution ETF (ARKG A-) deliver broad genomics exposure. However, ARKG is all the more relevant in this conversation because it’s an actively managed fund in an ETF category mostly littered with index-based strategies.

Active management is potentially rewarding for genomics investors because innovations emerge rapidly, often carrying with them significant long-term implications. That’s true of cell and gene therapies for neurodegenerative diseases.

“We expect therapies will target the rarest neurodegenerative diseases given the high unmet need, lack of treatment options, and poor understanding of these diseases,” noted Fitch Solutions. “Increasing cell and gene therapy approvals generally and the FDA’s aim to evaluate their safety and efficacy for neurodegenerative diseases will encourage further research and development.”

Developing cell and gene therapies requires significant expertise and is costly with no guarantee of future approvals by regulators. As a result, current and prospective ARKG member firms engaged in these fields may work collaboratively with partners to lower costs and potentially boost success rates.

Potentially adding to the long-term outlook for ARKG on the cell and gene therapies front, is that there is significant, unmet demand for treatments for conditions such as ALS, Huntington’s disease, and Duchenne muscular dystrophy.

“There are limited effective treatment options available for patients suffering from rare neurodegenerative diseases such as ALS, Huntington’s disease, and Duchenne muscular dystrophy. We, therefore, anticipate that rare neurodegenerative diseases will be at the forefront of research and development in the CNS gene and cell therapy space,” added Fitch.

Another point that could work in ARKG’s favor is that cell and gene therapies are increasingly a point of emphasis for the Food & Drug Administration (FDA). Roughly half the approved therapies in these fields arrived in 2019, indicating there’s ample room for growth on the regulatory front.

“The FDA’s five-year plan for rare neurodegenerative diseases, released in June 2022, outlines a safety project that it will conduct over FY23 and FY24 to gather information for cell and gene therapies to help inform the design of clinical trials for ALS and other neurodegenerative diseases,” concluded Fitch.

For more news, information, and analysis, visit our Disruptive Technology Channel.

Loading Articles...
Help & Info
  • Contact Us
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X